RAAV03

RAAV03 is a preclinical-stage polymeric conjugate being developed by Remab Therapeutics to address a major barrier in adeno-associated virus (AAV)-based gene therapy. The drug is designed for the selective intracorporeal removal of preexisting anti-AAV neutralizing antibodies (NAbs) from the patient's bloodstream. These antibodies are a significant obstacle as they can recognize and neutralize viral vectors, thereby reducing gene transfer efficiency and excluding many patients from treatment eligibility. By selectively depleting these harmful antibodies, RAAV03 aims to expand the pool of patients eligible for gene therapies and potentially enable safe and effective redosing strategies, which are often compromised by immune responses following initial administration.